1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Allgens Medical Technology Co. Ltd. Class A

Allgens Medical Technology Co. Ltd. Class A

SSSE:688613
18.30
CNY
+0.70
(+3.98%)
0.04EPS
203.15P/E
1.93BMarket Cap
Oct 31Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.13
1.27
1.69
1.84
1.97
1.83
1.71
1.46
1.62
1.66
Basic EPS, GAAP
0.29
0.34
0.68
0.89
1.01
0.71
0.41
-0.09
0.1
0.07
Free Cash Flow per Basic Share
0.03
-0.2
0.11
0.28
0.57
0.42
0.23
-0.23
0.08
- -
Dividend per Share
- -
- -
0.02
0.01
0.01
0.3
0.13
0.08
0.02
0.01
Book Value per Share
3.12
4.38
5.33
6.23
9.33
9.77
10.37
10.35
10.47
10.49
Tangible Book Value per Share
3.05
4.1
5.06
5.97
9.15
9.6
10.2
9.98
10.12
10.14
Basic Weighted Avg Shares
81
97
100
100
120
134
132
141
138
138
Sales/Revenue/Turnover
91
124
169
184
236
245
226
206
224
229
Operating Margin (%)
30.39
27.29
100
54.09
51.15
33.94
14.51
-8.38
-1.7
-2.75
Depreciation Expense
4
6
7
13
13
18
18
18
22
- -
Net Income, GAAP
24
33
68
89
121
95
54
-13
14
10
Effective Tax Rate (%)
14.33
19.69
13.89
14.66
10.59
4.68
- -
- -
22.67
33.02
Profit Margin (%)
25.75
26.67
40.21
48.4
51.17
38.82
23.95
-6.15
6.19
4.18
Working Capital
250
309
403
482
1,066
1,094
1,150
1,144
1,142
1,166
LT Debt
- -
- -
44
52
62
46
48
46
11
24
Total Equity
312
452
564
652
1,271
1,326
1,404
1,420
1,447
1,448
Return on Invested Capital (%)
- -
7.3
12.02
13.09
11.64
6.69
- -
- -
0.63
0.37
Return on Capital (%)
- -
10.06
13.61
13.94
12.29
7.34
- -
- -
1.35
0.93
Return on Common Equity (%)
- -
8.79
13.96
15.39
12.94
7.48
4.04
-0.91
0.98
0.67

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
37
3
6
LT Borrowings
7
5
20
LT Finance Leases
5
7
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
137
137
137
Market Capitalization
2,783
2,850
1,933

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,224
1,168
1,192
Cash, Cash Equivalents & STI
1,083
1,020
1,012
Accounts Receivable, Net
27
38
51
Inventories
77
80
76
Total Current Liabilities
82
22
27
Payables & Accruals
- -
- -
- -
ST Debt
37
3
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.66%
1.93%
Free Cash Flow
- -
-53.4%
-131.98%
Net Income, GAAP
- -
-72.21%
-209.3%
Sales/Revenue/Turnover
- -
4.85%
8.59%
Total Cash Common Dividend
- -
590.9%
-78.84%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
47
53
48
58
206
2025
42
58
- -
68
224
2026
49
55
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.02
-0.03
-0.13
-0.09
2025
0.01
0.05
- -
- -
0.1
2026
0.01
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
0.06
- -
0.08
2025
0.01
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zhi Ye Qiu
Full Time Employees
281
Sector
Health technology
Industry
Medical specialties
Address
3rd Floor, Building 35, Phase 2 Beijing BE China 102609
IPO Date
May 21, 2021
Website
allgensmed.cn
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Allgens Medical Technology Co., Ltd. Allgens Medical Technology CO., LTD. (688613.SS) engages in the research, development, production, and sale of high-end implantable medical devices and biomedical materials for tissue regeneration and repair, primarily biomimetic mineralized collagen artificial bone repair products; its main offerings include Igium Gold and BonGold for orthopedic bone defect repair, Tooth Shell for oral and plastic surgery applications, and Turui for neurosurgery, with over 50 varieties across orthopedics, stomatology, plastic surgery, and neurosurgery, sold to agents and terminal hospitals mainly in China. Founded in 2004 and headquartered in Beijing, China, the company operates a 10,000-level clean production workshop in the Zhongguancun Medical Device Park, Daxing District, and holds more than 50 Chinese patents plus over 10 overseas patents, including three NMPA Class III registrations and US FDA 510(k) clearances, with products used in over 200,000 clinical cases. In May 2021, Allgens listed on the Shanghai Stock Exchange STAR Market; in late 2023, it acquired 100% equity of German firm HumanTech Dental GmbH to expand dental implant capabilities, enhance transnational technology synergies, and broaden its product matrix for one-stop dental solutions.